News of Novartis AG' $2.1bn acquisition of Endocyte Inc., and the company's corresponding expansion into radiopharmaceuticals, dominated much of the discussion during the drug maker's third quarter earnings call Oct. 18. But the company's plate is chock full, with several high-profile drug launches underway.
The company provided updates on a number of commercial-stage drugs, including Cosentyx (secukinumab), Kymriah (tisagenlecleucel), Kisqali (ribociclib) and Aimovig (erenumab), as well as announcing regulatory news on its late-stage pipeline...